Biogen Inc. sees a notable uptick in stock price following strong quarterly earnings and promising developments in Alzheimer's treatment.
Biogen Inc. (NASDAQ:BIIB) is rising today, reflecting a positive market response to its recent earnings report and advancements in its Alzheimer's drug pipeline. The stock closed at CA$225.12, up 2.76% in today’s session.
Advertisement
Biogen Inc
BIIB.US
BIIB.US
Biogen Inc
WealthAwesomeMarket cap
$31.84B
P/E
38.3x
52W high
$225.80
52W low
$135.39
1W change
+0.79%
Beta
0.17
Analyst Price Targets
Based on 37 analysts covering BIIB · as of Sep 21, 2026
Wall Street analysts forecast BIIB stock price to rise 8.7% over the next 12 months.
Consensus
Buy3.81 / 5.00
Avg. Target
C$238.18
+8.7% Upside
Previously C$237.19 on Sep 17, 2026
Current Price
C$219.07
Last close
Analyst Breakdown (37 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BIIB's historical volatility
30-Day Vol
27.4%
Annualized
90-Day Vol
38.1%
Annualized
Trend (90d)
+34.2%
Annualized drift
90d Mean
C$247.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$228.16 | C$207.59 – C$250.77 |
| 60 trading days | C$237.63 | C$207.91 – C$271.60 |
| 90 trading days | C$247.49 | C$210.13 – C$291.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are encouraged by Biogen's robust earnings performance and the potential growth of its Alzheimer's treatments, positioning the company favorably within the biotechnology sector.
Biogen's stock up 2.76% following strong earnings.
Advertisement
The company's revenue of $2.74 billion, a 3.4% year-on-year increase, significantly exceeded analysts' expectations, contributing to the stock's rise today.
Bull case
Biogen's strong quarterly earnings, with revenues surpassing expectations by 12.1%, along with advancements in its Alzheimer's drug Leqembi, boost investor confidence and suggest a positive trajectory for the company. This performance shows that Biogen is effectively navigating the competitive biotechnology landscape, particularly in neurology.
Bear case
Despite the positive momentum, investors should stay cautious about potential market volatility and regulatory challenges that could affect Biogen’s growth. The competitive landscape for Alzheimer’s treatments remains a concern, and these factors could impact future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
